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ABSTRACT Human adenovirus (Ad) E1A proteins have long been known as the
central regulators of virus infection as well as the major source of adenovirus onco-
genic potential. Not only do they activate expression of other early viral genes, they
make viral replication possible in terminally differentiated cells, at least in part, by
binding to the retinoblastoma (Rb) tumor suppressor family of proteins to activate
E2F transcription factors and thus viral and cellular DNA synthesis. We demonstrate
in an accompanying article (F. Dallaire et al., mSphere 1(1):e00014-15, 2015) that the
human adenovirus E3 ubiquitin ligase complex formed by the E4orf6 and E1B55K
proteins is able to mimic E1A activation of E2F transactivation factors. Acting alone
in the absence of E1A, the Ad5 E4orf6 protein in complex with E1B55K was shown
to bind E2F, disrupt E2F/Rb complexes, and induce hyperphosphorylation of Rb,
leading to induction of viral and cellular DNA synthesis, as well as stimulation of
early and late viral gene expression and production of viral progeny. While these ac-
tivities were signiﬁcantly lower than those exhibited by E1A, we report here that this
ligase complex appeared to enhance E1A activity in two ways. First, the E4orf6/
E1B55K complex was shown to stabilize E1A proteins, leading to higher levels in in-
fected cells. Second, the complex was demonstrated to enhance the activation of
E2F by E1A products. These ﬁndings indicated a new role of the E4orf6/E1B55K li-
gase complex in promoting adenovirus replication.
IMPORTANCE Following our demonstration that adenovirus E3 ubiquitin ligase
formed by the viral E4orf6 and E1B55K proteins is able to mimic the activation of
E2F by E1A, we conducted a series of studies to determine if this complex might
also promote the ability of E1A to do so. We found that the complex both signiﬁ-
cantly stabilizes E1A proteins and also enhances their ability to activate E2F. This
ﬁnding is of signiﬁcance because it represents an entirely new function for the li-
gase in regulating adenovirus replication by enhancing the action of E1A products.
KEYWORDS: adenovirus, ubiquitin ligase, E4orf6, E1B55K, E1A
The major regulators of human adenovirus replication are the products of earlyregion 1A (E1A), which encodes a series of species, notably products of the 13S
(289R) and 12S (243R) E1 mRNAs (1). Both interact with the retinoblastoma (Rb) protein
and other members of the “pocket” protein family that regulate E2F transcription
factors through complex formation with transcriptional repression complexes (2, 3).
Binding by E1A products frees E2F to induce expression of both early viral transcripts
and cell cycle genes that regulate the initiation of DNA synthesis, thus permitting
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replication even in terminally differentiated epithelial cells, the major targets of human
adenoviruses (Ads) (4–6). In addition, E1A 289R contains a transcriptional activation
domain that promotes transcription of early viral genes (7). Thus, E1A products act early
after infection to activate expression of viral genes required for replication and to
promote conditions for effective viral DNA synthesis. Both the 13S/289R and 12S/243R
E1A proteins are known to exhibit very short half-lives in infected cells (8, 9). Two
regions of E1A proteins contribute to this property: one near the N terminus, which
interacts with 19S proteasomal proteins (10, 11), and PEST sequences in the C terminus,
in which phosphorylation is crucial to target E1A products to proteasomes (10).
The early adenovirus E4orf6 and E1B55K products have been shown in all human
adenovirus species to form functional cullin-based E3 ubiquitin ligase complexes that
enhance viral replication by degrading a number of cellular proteins (12–14). The E4orf6
protein associates via multiple BC boxes with cellular elongins B and C to facilitate
binding of either Cul5 or Cul2 and other components to form the core ligase complex
(13, 15–18). E1B55K associates with E4orf6 only when present in the ligase complex, as
E4orf6 BC box mutants do not interact with E1B55K (17). E1B55K is believed to function
as the major substrate acquisition component of the ligase complex. Although a
number of substrates of the ligase have already been identiﬁed (17–30), additional
functions could exist that enhance viral replication.
In an accompanying article (31), we demonstrate that when expressed at high levels,
the E4orf6/E1B55K complex mimics E1A activation of E2F transcription factors by
inducing hyperphosphorylation of Rb and disrupting the Rb/E2F complex. Here we
show that this complex both signiﬁcantly stabilizes E1A proteins and appears to
enhance the ability of E1A products to disrupt E2F/Rb complexes and activate E2F.
These ﬁndings suggest a new and important function for the ligase complex in
adenovirus infection.
RESULTS
The E4orf6/E1B55K complex mimics E1A functions even at low levels typical of
virus-infected cells. In our previous studies, described in reference 31, we reported
that, when expressed at high levels in the absence of E1A products, the Ad5 E4orf6/
E1B55K ligase complex could induce the hyperphosphorylation of Rb, disrupt Rb/E2F
complexes, and activate E2F-dependent transcription. These effects were more modest
than those induced by E1A. Nevertheless they appeared to be dependent on the
formation of the E4orf6/E1B55K ligase complex and may result from an interaction of
E4orf6 proteins with E2F transcription factors. One concern in these studies was that
although the E4orf6/E1B55K complex clearly was able to mimic E1A functions related
to activation of E2F, with resulting effects on DNA synthesis and virus production, it was
possible that these effects only occur when E4orf6 and E1B55K are expressed at high
levels, far in excess of those routinely detected in wild-type virus-infected cells. To
address this issue, two types of study were conducted. Experiments in our previous
studies were performed with infection by viral vectors at a multiplicity of infection
(MOI) of 35, as done previously in our screen for ligase substrates (22, 32). To determine
if expression of E4orf6 and E1B55K induced these effects at lower levels, H1299 cells
were infected with AdE4orf6 and AdE1B55K at MOIs of 5, 15, and 35. As shown in
Fig. 1A, reduced levels of E4orf6 and E1B55K were seen at lower MOIs, but nevertheless
signiﬁcant induction of viral DNA synthesis, hyperphosphorylation of Rb, and cyclin E,
hexon, and DNA binding protein (DBP) levels were apparent, even at an MOI of 5
although the effects were somewhat reduced. To address this issue further, studies
were conducted in which we attempted to match directly the levels of E4orf6 and
E1B55K present in cells infected by wild-type Ad5 at an MOI of 20. Cells were infected
with AdLacZ vector and cotransfected with increasing amounts of plasmid DNAs
expressing either E4orf6 or E1B55K. Figure 1B shows that the levels of these
products in wild-type-infected cells at 24 h postinfection (p.i.) (lane 1) were compa-
rable to those in AdLacZ-infected cells transfected by the smallest amounts of plasmid
DNAs (lane 4) in which signiﬁcant hyperphosphorylation of Rb and increased cyclin E,
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hexon, and DBP levels were apparent relative to mock-infected (lane 2) and AdLacZ-
infected (lane 3) cells. While the outcome, as in previous studies, was much less than
with wild-type virus, these results indicated clearly that the complex can elicit its effects
even at levels of E4orf6 and E1B55K normally present in virus-infected cells.
E4orf6 increases the stability of E1A products. E1A plays an important essen-
tial role in activating E2F to promote efﬁcient viral replication and induction of viral and
cellular DNA synthesis (33–36). Given our recent ﬁndings, we wondered what effect
E4orf6/E1B55K might have in a context where E1A was also present. Both the 13S/289R
and 12S/243R E1A proteins are known to exhibit very short half-lives in infected cells
(8, 9), and thus changes in their synthesis or stability could affect the infectious cycle.
To determine if the E4orf6/E1B55K complex affects E1A protein levels, plasmid DNAs
expressing either the 12S or 13S E1A products were transfected into H1299 cells either
alone or along with those expressing E4orf6 and E1B55K. Figure 2A shows that in both
cases, expression of E4orf6/E1B55K signiﬁcantly increased the levels of E1A products.
This ﬁnding was somewhat surprising because, as discussed above, the viral ligase
normally acts to degrade a variety of substrates. (It was also evident in Fig. 2A that by
reducing the amount of E1A-expressing plasmid DNAs, levels similar to those seen with
E1A alone could be achieved in the presence of E4orf6/E1B55K. This manipulation will
be of importance in experiments described below in which we attempt to measure the
effects of the E4orf6/E1B55K complex on E1A functions.) One obvious explanation for
these increased E1A levels could be that E1A proteins are more stable in the presence
of the E4orf6/E1B55K complex. To examine this possibility, cells were transfected with
plasmid DNAs expressing 13S/289R E1A protein in the presence or absence of those
encoding E4orf6/E1B55K, and after 43 h, cycloheximide was added for increasing times
and the levels of E1A protein were measured by quantifying scans of E1A Western blots.
Figure 2B shows the amounts of 13S E1A protein at various times following cyclohex-
imide treatment. From these data, the half-life values were calculated, indicating that
expression of E4orf6/E1B55K signiﬁcantly increased the E1A half-life from 2.09 h in the
control to 3.56 h, an effect consistent with the observed increased E1A levels shown in
Fig. 2A. Similar results were seen with 12S E1A (data not shown). To determine if E4orf6
and E1B55K also affect the stability of E1A proteins in the context of an infection, H1299
cells were infected with wild-type virus, as well as mutant viruses in which the E4orf6
or E1B55K genes were deleted. Cells were lysed at 4-h intervals, and E1A, DBP, E4orf6,
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FIG 1 Effects of E4orf6 and E1B55K at low-level expression. (A) H1299 cells were infected for 48 h with the indicated
viral vector at the indicated MOIs and complemented with AdLacZ for an even total of virus particles for each set.
Whole-cell extracts were immunoblotted as indicated using the appropriate antibodies, and PCR for the fiber gene was
performed. (B) H1299 cells were transfected with increasing amounts of cDNAs expressing E4orf6 and E1B55K and
infected with AdLacZ at the indicated MOI for 48 h or infected with wild-type virus at an MOI of 20 for 24 h. Whole-cell
extracts were immunoblotted as indicated using the appropriate antibodies.
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and E1B55K protein expression levels were examined by Western blotting with actin as
a control. Figure 2C shows that deletion of the E4orf6 or E1B55K genes caused a
reduction in the levels of E1A present, an effect not seen with another E4 mutant
lacking E4orf4 (data not shown). Reduction of E1A levels was not due to differences in
the proportion of infected cells in the population as analysis by immunoﬂuorescence
microscopy using anti-DBP antibodies indicated a similar percentage of positive cells in
all cultures (Fig. 2C, bottom). Thus, these ﬁndings were consistent with a role for E4orf6
and E1B55K in stabilizing E1A proteins. Interestingly, Fig. 2C shows that deletion of
E4orf6 or E1B55K resulted in some reduction of DBP levels, consistent with the effect
that the E4orf6/E1B55K complex had in inducing the E2E promoter (31). To determine
if both E4orf6 and E1B55K function to stabilize E1A proteins, H1299 cells were trans-
fected with plasmid DNAs expressing HA-E1A, E4orf6, or E1B55K, and extracts were
analyzed by Western blotting. Figure 2D shows that E4orf6 alone could induce a
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FIG 2 E4orf6/E1B55K increases the stability of E1A. (A) H1299 cells were transfected with plasmid DNA expressing E4orf6, E1B55K,
and various amounts of E1A as indicated for 48 h. Whole-cell extracts were immunoblotted as indicated using the appropriate
antibodies. (B) H1299 cells were transfected with plasmid DNAs expressing E4orf6, E1B55K, and 13S E1A for 43 h followed by 0 to
5 h after addition of 25 g/ml cycloheximide. Whole-cell extracts were immunoblotted using E1A antibodies, and the blots were
scanned and quantified with ImageJ. Each condition was normalized to its time zero (average of three experiments). (C) H1299 cells
were infected with the indicated viruses at an MOI of 5 and harvested at the indicated times. Whole-cell extracts were immunoblotted
as indicated using the appropriate antibodies. WT virus, H5pg4100; E4orf6-deleted, H5pm4154; E1B55K-deleted, H5pm4149. (D)
H1299 cells were transfected with plasmid DNAs expressing E4orf6, E1B55K, and E1A as indicated for 48 h. Whole-cell extracts were
immunoblotted as indicated using the appropriate antibodies.
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signiﬁcant increase in E1A protein, whereas E1B55K alone exhibited only a small
increase. These results suggested that E4orf6 might play a greater role in the stabili-
zation of E1A products.
To explain this effect on E1A stability, we determined if E4orf6 interacts with E1A
products. Figure 3A shows that E4orf6 interacted with multiple forms of both 13S and
12S E1A products. No such interaction was observed in similar studies with E1B55K
alone (data not shown). This interaction between E1A and E4orf6 proteins was also
detected during virus infection. H1299 cells were infected with wild-type dl309 virus or
the AdE4orf6 vector expressing E4orf6 as a negative control for the expression of E1A,
and lysates were immunoprecipitated using anti-E1A antibodies. Figure 3B shows that
the E4orf6-E1A interaction also was evident during virus infection. These results sug-
gested that interactions between E1A products and E4orf6 might be responsible for
increases in E1A stability. Although we have not conducted an extensive analysis of the
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FIG 3 E4orf6 binds at the N terminus of E1A proteins. (A) H1299 cells were transfected with plasmid
DNAs expressing E4orf6, 12S E1A, and 13S E1A proteins as indicated, and at 48 h, immunoprecipi-
tates were obtained using E4orf6 antibodies as well as whole-cell extracts were immunoblotted as
indicated using appropriate antibodies. (B) H1299 cells were infected with the indicated WT virus or
negative-control AdE4orf6 viral vector for 24 h at MOIs of 20 and 5, respectively, to obtain similar
expression levels of E4orf6 protein. Immunoprecipitates obtained using antibodies against E1A
proteins as well as whole-cell extracts were immunoblotted as indicated using the appropriate
antibodies. (C) H1299 cells were infected as indicated with WT virus (dl309) or E1A dl1101 (4-25),
dl1102 (26-35), or dl1504 (1-14) mutant viruses at an MOI of 20 FFU/cell and coinfected with
AdE4orf6 or AdLacZ viral vectors at an MOI of 5 for 24 h. Immunoprecipitates obtained using E4orf6
antibodies as well as whole-cell extracts were immunoblotted as indicated using the appropriate
antibodies.
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E4orf6-E1A protein interactions, Fig. 3C shows studies using E1A mutants lacking
various regions toward the N terminus. The results indicated that binding to E1A
products requires a region at the N terminus between residues 1 and 25 (the dl1101
and dl1504 mutants) but not residues 26 to 35 (the dl1102 mutant). This N-terminal
region corresponded to residues shown previously to be involved with interactions
with 19S proteasomal proteins (10, 11). Thus, binding of E4orf6 might enhance E1A
stability by inhibiting such interactions to slow degradation by the proteasome.
E4orf6 and E1B55K enhance E1A effects on E2F. In addition to effects on E1A
protein levels, we wondered if the interactions of E4orf6 protein with E2F and E1A
products might enhance the ability of E1A to activate E2F and promote viral replication.
We ﬁrst examined effects on Rb phosphorylation and expression of two products of
E2F-regulated genes. It is important to note that to address this question, it was
essential to conduct studies using equal amounts of E1A products, as expression of the
E4orf6/E1B55K complex augments E1A levels. Thus, we utilized the protocol shown in
Fig. 2A in which we reduced the level of plasmid DNA encoding E1A products in the
presence of E4orf6 and E1B55K. Figure 4A shows that this manipulation yielded
relatively similar levels of E1A 13S/289R in the presence and absence of E4orf6/E1B55K.
Figure 4A also shows that expression of E1A induced a signiﬁcant shift in Rb gel
migration; however, this effect was considerably enhanced when E1A was coexpressed
with E4orf6 and E1B55K. Figure 4A also shows by Western blotting using the appro-
priate antibodies that expression of either E4orf6/E1B55K or E1A 13S/289R enhanced
expression of the E2F-regulated genes encoding cyclins E and A, but even higher levels
were evident when all were coexpressed. These results suggested that coexpression of
the ligase complex is able to enhance signiﬁcantly the levels of both Rb phosphoryla-
tion associated with activation of E2F and expression of products of two E2F-regulated
genes above those obtained with E1A alone. We also examined the ability of E1A
products to disrupt E2F/Rb complexes. Figures 4B (13S) and C (12S) show results
obtained when hemagglutinin (HA)-E2F1 was expressed in the presence or absence of
E4orf6/E1B55K and 13S or 12S E1A proteins expressed from plasmid DNAs, after which
extracts were immunoprecipitated with anti-E2F1 antibodies and then analyzed by
Western blotting using either anti-Rb or anti-HA antibodies. Control Western blotting
analyses of total cell extracts indicated the levels of all products. The results indicated
that although expression of either E4orf6/E1B55K or E1A proteins reduced the level of
Rb associated with HA-E2F1, expression of all enhanced this effect greatly, reaching
levels comparable to those seen during infection with viral vectors expressing E4orf6
and E1B55K (lane to the right of each panel) and as found previously by many groups
in wild-type virus infection (33, 37–39). (Note that E1B55K protein expressed from the
viral vector contains a 6His and heart muscle kinase site (HMK) tag, thus explaining
why it migrated more slowly.)
E4orf6 and E1B55K enhance E1A effects on viral replication. We also deter-
mined if coexpression of E4orf6/E1B55K with E1A products could enhance the viral life
cycle. Figure 5A shows that expression of only E4orf6 and E1B55K in combination with
control AdLacZ viral vector infection resulted in some expression of late proteins, as
shown previously in reference 31. Expression of only 12S E1A also resulted in a low level
of late protein expression. Interestingly, the combination of 12S E1A with E4orf6/
E1B55K resulted in much higher levels of late protein expression, demonstrating a
synergistic effect. Expression of 13S E1A alone was sufﬁcient to induce high expression
of late proteins and was not increased by expression of E4orf6 and E1B55K. Also of
interest, cyclin E levels correlated much more with the expression of E4orf6 and E1B55K
than with either form of E1A. We have observed previously in a time course experiment
(data not shown) that in replicating cells, cyclin E expression ﬁrst increases and then
decreases. Thus, it was not surprising in this experiment, in which replication occurred
(expression of both E4orf6 and E1B55K and infection with AdLacZ vector), that there
was less cyclin E than would be expected due to a synergy effect, since that time point
was past the peak expression of cyclin E. Figure 5B shows that a similar synergy was
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seen for the production of progeny virions. H1299 cells were infected with AdLacZ and
cotransfected with plasmid DNAs expressing E1A 12S/243R, E4orf6, E1B55K, or all or
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with plasmid DNA expressing E1A 13S/289R, and after 48 h cell extracts were subjected
to plaque assays on 293 cells, as described in Materials and Methods. Whereas expres-
sion of either E4orf6/E1B55K or E1A 12S/243R led to low levels of replication of AdLacZ
vector, their coexpression led to production of high levels of virus, higher even than
those observed with expression of E1A 13S/289R alone. Finally, we returned to the
concern that effects of the ligase complex to enhance E1A activity might result from the
high levels of expression of E4orf6/E1B55K. Thus, a study was conducted in which these
species were expressed at low levels from plasmid DNAs along with 12S E1A protein in
cells infected at an MOI of 17.5 by the AdLacZ vector. Although in our previous studies
we examined effects on hyperphosphorylation of Rb and separation of the E2F-Rb
complex, assays measuring these effects were not sufﬁciently quantitative to determine
if the E4orf6/E1B55K complex results in a partial enhancement of E1A activity. Thus, we
examined by Western blotting the effects on production of late hexon protein, cyclin
E, and DBP, which is produced as a result of activation of E2F. Figure 5C shows that the
levels of E4orf6 and E1B55K proteins (lanes 4 and 6) following transfection were quite
similar to those present in cells at 24 h following infection by wild-type virus (lane 1).
Expression of both 12S E1A and E4orf6/E1B55K induced an increase in the amount of
hexon from the AdLacZ genome (lanes 5 and 4); however, a larger increase was
observed when all proteins were expressed (lane 6). A similar but smaller increase was
also seen for the expression of E2F-inducible DBP (short exposure). The increase in the
level of DBP induced by E4orf6 and E1B55K expression can be seen in the longer
exposure. Interestingly, 12S E1A induced only a small amount of cyclin E (lane 5),
whereas expression of E4orf6/E1B55K in the presence (lane 6) or absence (lane 5) of E1A
yielded considerably more, suggesting that the ligase complex plays a signiﬁcant role
in inducing expression of at least this E2F-dependent species (discussed more in the
Discussion). Thus, in total our ﬁndings indicated that in addition to other known
functions in viral replication, the E4orf6/E1B55K complex plays an important and
previously undescribed role in enhancing the effects of E1A products on events of the
virus life cycle.
DISCUSSION
In the present report, we have extended our recent ﬁndings that the Ad5 E4orf6/
E1B55K complex displays an E1A-like ability to activate transcription factor E2F to
promote viral replication. We demonstrated that this ability is not simply the result of
overexpression of these viral proteins, and provided evidence that, via at least two
mechanisms, the E4orf6/E1B55K complex may enhance the ability of E1A products to
sustain an efﬁcient replicative cycle. E1A is clearly the critical initiating factor in the
activation of E2F; however, our results suggested the possibility that following the
activation of expression of early viral products by E1A, newly formed E4orf6/E1B55K
complexes may function to amplify and sustain these initial effects of E1A to maximize
viral replication.
The E4orf6/E1B55K complex may enhance E1A activity in at least two ways. It was
shown here to increase the half-life of E1A products, and in both plasmid-based assays
and in infected cells, to signiﬁcantly augment the levels of E1A products to better elicit
their effects. As discussed above, this effect may largely be due to interactions of the
E4orf6 protein with E1A products, and preliminary results with E1A mutant proteins
shown in Fig. 3C suggested that such stabilization may result at least in part from the
association of E4orf6 with an N-terminal region of E1A products involved in interactions
with the 19S proteasomal proteins. Such interactions could inhibit or slow E1A protein
degradation to increase half-life.
Also of great interest were the effects of the E4orf6/E1B55K complex on the
Figure Legend Continued
small amounts of plasmid DNAs expressing E4orf6 and E1B55K and infected with AdLacZ at an MOI
of 17.5 for 48 h or infected with wild-type virus at an MOI of 20 for 24 h. Whole-cell extracts were
immunoblotted as indicated using the appropriate antibodies.
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activation of E2F transcription factors and their role in inducing early viral gene
expression and DNA synthesis. Our ﬁndings indicated that coexpression of E1A prod-
ucts with a functional E4orf6/E1B55K ligase complex enhanced the hyperphosphory-
lation of Rb and separation of the inhibitory E2F/Rb complex, leading to higher levels
of expression of E2F-responsive genes. While some of these studies were conducted at
E4orf6/E1B55K levels in excess of those normally present in virus-infected cells, signif-
icant effects were also observed at low levels similar to those seen in infection. The clear
ability of the complex at low levels to enhance the E2F-dependent expression of cyclin
E and DBP (Fig. 5C) supports the idea that the E4orf6/E1B55K complex may signiﬁcantly
enhance the ability of E1A products to activate E2F. The extent of this enhancement
and its importance in optimizing wild-type adenovirus replication will require addi-
tional studies. It is also still unclear how the E4orf6/E1B55K complex might enhance the
ability of E1A products to carry out these activities. We found that E4orf6 protein
interacts with both E2F and E1A products, and thus such interactions may enhance
complex dissociation induced by the well-known interaction between E1A proteins and
Rb family members (40–42); however, to enhance E1A effects on E2F, a functional ligase
complex is required, suggesting that this process involves more than enhanced inter-
actions with the E2F/Rb complex.
At ﬁrst glance it may be surprising that E1A had such a small effect on the separation
of Rb/E2F1 complexes (Fig. 4B and C); however, it has been shown that this interaction
is difﬁcult to disrupt by E1A due to an additional speciﬁc interaction of E2F1 with Rb
that does not exist with other E2F species (43). Since E4orf6/E1B55K can disrupt E2F/Rb
complexes for E2F1 to -3, our ﬁndings may suggest that the mechanism for separation
of E2F/Rb complexes is different from that with E1A but may also potentially be
complementary.
As a ﬁnal note, it is interesting to speculate on the role that this E1A-like function
might have in the evolution of adenoviruses. It is unknown if the E1A-like properties
reported here are shared by E4orf6/E1B55K complexes of other human serotypes or
species or in fact other adenoviruses. Genomic analyses of animal adenoviruses indi-
cated the coevolution of sequences encoding E4orf6- and E1B55K-like proteins. In
addition to the Mastadenovirus genus (which includes all human adenoviruses), E4orf6-
and E1B55K-like sequences are present in the Atadenovirus genus, which lacks any
E1A-like sequences (http://www.vmri.hu/~harrach/AdVtaxlong.htm). These ﬁndings
suggested the possibility that the E1A-like function of the E4orf6/E1B55K complex
could represent the original capacity of more primitive adenoviruses to replicate in
terminally differentiated target cells. Of course, this faculty was greatly enhanced with
the evolution of E1A proteins, which evolved with a much greater capacity to induce
early viral gene expression and activate E2F. Clearly more research will be required to
address these and other questions related to this new role for the E4orf6/E1B55K
complex.
MATERIALS AND METHODS
Cell lines, plasmids, and viruses. Human non-small-cell lung carcinoma H1299 cells (ATCC CRL-5803)
and embryonic kidney 293 cells (HEK-293; ATCC CRL-1573) were grown in Dulbecco’s modiﬁed
Eagle’s medium (Gibco) without antibiotics and supplemented with 10% fetal bovine serum
(Multicell) at 37°C in 5% CO2. The plasmids used in the studies were pcDNA3-E4orf6 (44), pcDNA3-
E1B55K (45), pcDNA3-HA-E1A-12S and pCDNA3-HA-E1A-13S (46), and pcDNA3-HA-E2F1 (kindly
provided by Doron Ginsberg). The adenoviral vectors and virus mutants used have been described
previously: AdE1B55K (47, 48), AdE4orf6 (47, 48), AdLacZ (49), H5pg4100 (WT) (50), H5pm4154
(E4orf6) (51), H5pm4149 (E1B55K) (52), and the dl309 (53) and E1A dl1101, dl1102, and dl1504
mutant (54) viruses.
Antibodies and reagents. The rabbit polyclonal antibodies used were E4orf6 (1807) (55) and Ad5
capsid (56). The mouse monoclonal antibodies used were as follows: Ad5 E1B55K 2A6 (57), E2A
DNA-binding protein B6-8 (58), actin C4 (catalog no. 691001; MP Biomedicals), Rb OP66 (catalog no.
OP66; Millipore) or 4H1 (catalog no. 9309; Cell Signaling), cyclin A BF683 (catalog no. Sc-239; Santa Cruz),
HA tag HA.11 clone 16B12 (catalog no. MMS-101R; Covance), E2F1 KH95 (catalog no. Sc-251; Santa
Cruz), Ad5 E1A M58 (from Roger Grand), and M73 (59), cyclin E HE12 (catalog no. sc-241; Santa Cruz).
The rat monoclonal antibody was E1B55K 4E8 (52). The horseradish peroxidase (HRP)-conjugated
secondary antibodies for detection in Western blotting were goat anti-mouse IgG, goat anti-rabbit
IgG, and goat anti-rat IgG (Jackson ImmunoResearch Laboratories) and rat anti-mouse  light-chain-
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speciﬁc clone 187.1 (catalog no. 559751; BD Biosciences). Additional reagents included Lipo-
fectamine 2000 reagent (Invitrogen) and cycloheximide (catalog no. CYC003.5; BioShop).
DNA transfections and infections. DNA transfections were done using Lipofectamine 2000 reagent
according to the manufacturer’s recommendations. The ﬁnal amounts of DNA per well were equalized
by addition of vector plasmid pcDNA3. For infections, cells infected with viruses diluted in infection
medium (0.2 mM CaCl2, 0.2 mM MgCl2, and 2% serum in phosphate-buffered saline [PBS]) for 90 min
before removal and the addition of normal growth medium. For most experiments, a multiplicity of
infection (MOI) of 35 PFU per cell was used for viral vectors, except where indicated, and the ﬁnal
amounts of vectors were adjusted to be equal by the addition of AdLacZ. Infections with WT and mutant
viruses were done at 5 focus-forming units (FFU)/cell for coimmunoprecipitation (co-IP) experiments and
20 FFU/cell for infections in low-expression experiments. Infections with the dl309, dl1101, dl1102, and
dl1504 mutants were done at an MOI of 20 PFU/cells. For infections and cotransfections, cells were ﬁrst
infected at the indicated MOI for 90 min and then transfected with the indicated plasmid DNAs. Infection
for the time course experiment was done in normal medium at an MOI of 5 FFU per cells, and cells were
harvested at 4-h intervals from 8 h p.i. to 24 h p.i.
Protein extraction. Cells were washed with PBS and removed at different times postinfection/
posttransfection by incubation for 5 min with gentle agitation with 0.53 mM EDTA and collected by
centrifugation. For viral DNA ampliﬁcation of extracts and other protein blotting, cells were lysed for
20 min on ice in the lysis buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 5 mM EDTA, 1% NP-40, 0.1% SDS,
0.1% Triton X-100, protease inhibitor cocktail [Sigma], 1 mM Na3VO4, 10 mM NaPPi, 10 mM NaF) and
clariﬁed by centrifugation at 13,000 g for 10 min. For immunoprecipitation studies, cells were lysed for
20 min on ice in lysis buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 5%
glycerol, protease inhibitor cocktail [Sigma], 1 mM Na3VO4, 10 mM NaPPi, 10 mM NaF) and clariﬁed by
centrifugation at 13,000  g for 10 min.
Immunoblotting. Equal amounts of proteins were separated by SDS-PAGE and then transferred to
polyvinylidene diﬂuoride membranes (Millipore) blocked using 5% skimmed milk prior to antibody
blotting. Primary antibodies were added to the membranes for 2 to 3 h at room temperature or overnight
at 4°C. Membranes were washed with PBS containing 0.1% Tween 20, and the secondary antibody was
added for 1 h at room temperature. Detection was performed using Western Lightning Chemilumines-
cence Reagent Plus (PerkinElmer).
Viral DNA ampliﬁcation. H1299 cells were infected with Ad vectors expressing the appropriate
combination of E4orf6 and E1B55K or AdLacZ vector at the indicated MOI. Cell extracts were made as
described above and treated with proteinase K for 1 h at 55°C. Viral DNA content was measured by PCR
with primers speciﬁc for the Ad5 ﬁber gene (forward, CACCCCTCACAGTTACCTCAGAAGCCC, and reverse,
GTCTGTTTTGAGAATCAATCCTTAGTCCTC). PCR products were visualized on 1.2% agarose gels. Puriﬁed
adenovirus DNA was used as a positive control for PCR analyses.
Measurement of progeny virions. H1299 cells were infected with AdLacZ vector at an MOI of 35
and cotransfected with the indicated plasmids for 48 h. Cells were pelleted, lysed by 4 cycles of freezing
and thawing, and clariﬁed by centrifugation at 1,900  g for 10 min. Virus titers in the supernatant were
determined by plaque assay in HEK293 cells. A representative experiment is shown, with error bars from
an average of three independent plaque assays.
Immunoprecipitations. Cells were transfected or infected as indicated for each experiment.
Between 200 and 500 g of proteins was precleared overnight at 4°C with protein G Sepharose
beads (GenScript). Beads were removed by centrifugation, and supernatants were incubated with
either anti-E4orf6 polyclonal antibody 1807, anti-E1A mouse monoclonal antibody, or anti-E2F1
KH95 mouse monoclonal antibody, followed by incubation with protein G Sepharose (GenScript).
The beads were extensively washed in lysis buffer and examined by SDS-PAGE. The detection of Rb
and HA-tagged proteins in Western blots with primary mouse monoclonal antibodies was done with
secondary HRP-conjugated rat anti-mouse  light-chain-speciﬁc antibody.
Cycloheximide treatment. H1299 cells were transfected with indicated plasmids for 43 h at 37°C.
The medium was replaced by fresh medium containing 25 g/ml cycloheximide, cells were harvested at
the indicated time points, and protein extracts were made as indicated above. Samples were separated
by SDS-PAGE, transferred to polyvinylidene diﬂuoride membranes, and blotted as described earlier.
Autoradiography ﬁlms were scanned, and the HA-E1A band was analyzed and quantitated using ImageJ
1.42q software (NIH, United States). Each condition was normalized to the respective 0-h time point, and
error bars were from three independent experiments.
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